Jill received her B.S. in cell and molecular biology from University of Washington and her M.S. from Johns Hopkins University. Following completion of her studies, she held positions at Walter Reed Army Institute of Research, Rosetta Inpharmatics (subsidiary of Merck) and NuGen Technologies. Prior to joining DTx Pharma, she worked at Regulus Therapeutics where she led metabolic programs through preclinical proof of concept and gained significant experience in oligonucleotide biology.